St. Jude Children’s Research Hospital published a new method intended to improve detection of small off-target edits generated by base editors, the team said. The approach provides a higher-resolution assessment of rare off-target sites that can pose safety risks in therapeutic genome editing, addressing a major barrier for clinical translation and regulatory assessment. The method was released publicly to aid researchers and clinicians in assessing precision editors. Researchers emphasized that many optimization efforts for CRISPR-based therapies focus on minimizing unintended edits, yet technical hurdles have limited detection sensitivity. St. Jude’s platform aims to make off-target surveillance faster and more reliable, enabling better risk assessment for investigational gene therapies. Expect this tool to be incorporated into preclinical safety packages and to inform regulatory discussions on acceptable off-target thresholds.